Treatment Effects of Xuebijing Injection in Severe Septic Patients with Disseminated Intravascular Coagulation

Table 2

Baseline characteristics of patients.

	Control group (𝑛=83)	Intervention group (𝑛=88)	𝑃
Age (yrs)	56 (49–73)	59 (53–74)	0.14
Male (𝑛, %)	51 (61.45)	57 (64.77)	0.652
BMI	23.67±2.93	22.97±3.40	0.158
28-day mortality (𝑛, %)	29 (34.94)	18 (20.45)	0.034
Platelet (×10^9/L)	79.61±49.69	70.51±58.92	0.326
PT (s)	25.72±7.34	22.66±8.46	0.263
Fibrinogen (g/L)	2.64±1.47	2.57±1.93	0.17
D-dimer (mg/L)	4.7 (1.85–8.62)	5.2 (2.12–9.53)	0.192
INR	1.79±0.91	1.71±0.88	0.607
MEDS score	11 (8–19)	12 (9–21)	0.794
APACHE II score	24 (15–32)	26 (16–35)	0.334
Type of infection (𝑛, %)
Pneumonia	39 (46.88)	49 (55.68)	0.256
IAI	37 (44.58)	33 (37.5)	0.347
USI	7 (8.43)	6 (6.82)	0.69

BMI: body mass index; PT: prothrombin time; INR: international normalized ratio; MEDS score: Mortality in Emergency Department Sepsis score; APACHE II score: Acute Physiology and Chronic Health Evaluation II score; IAI: intra-abdominal infection; USI: urinary system infection.